Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gogas, H.
Right arrow Articles by Fountzilas, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gogas, H.
Right arrow Articles by Fountzilas, G.
Related Collections
Right arrow 2003 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:667-674, 2003
© 2003 European Society for Medical Oncology

The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer

H. Gogas1,+ and G. Fountzilas2

1 First Department of Medicine, Laiko Hospital, University of Athens, Athens; 2 AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

Received 7 August 2002; revised 24 December 2002; accepted 31 January 2003

The first 150 words of the full text of this article appear below.

Introduction

Neoadjuvant therapy for breast cancer generally refers to the administration of chemotherapy prior to local treatment with surgery and/or radiation. The biological rationale for neoadjuvant therapy of breast cancer is based on the observation of accelerated metastatic growth following tumor resection in animal models. It is suspected that in addition to decreasing the spread of metastatic disease, neoadjuvant chemotherapy can also minimize the emergence of chemoresistant clones. Additional rationale for the use of neoadjuvant chemotherapy is based on its potential clinical benefits, such as increasing tumor resectability by reducing the size of an unresectable tumor, improving local control and improving cosmesis by allowing breast-conserving treatment. It also offers an important test bed for novel therapies including new drugs and new combinations of drugs.

Paclitaxel was the first taxane to show activity in breast cancer. The introduction of paclitaxel into metastatic breast cancer (MBC) treatment has yielded encouraging results. It has . . . [Full Text of this Article]

Search for studies

Phase II studies with docetaxel

Randomized studies with docetaxel

Phase II studies with paclitaxel

Randomized trials with paclitaxel

Future prospectives


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
G. F. V. Woude, G. J. Kelloff, R. W. Ruddon, H.-M. Koo, C. C. Sigman, J. C. Barrett, R. W. Day, A. P. Dicker, R. S. Kerbel, D. R. Parkinson, et al.
Reanalysis of Cancer Drugs: Old Drugs, New Tricks
Clin. Cancer Res., June 1, 2004; 10(11): 3897 - 3907.
[Full Text] [PDF]